Matching-adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma

• DOI: 10.1159/000545891
• Publication Date: 2025-04-22T16:01:33Z
• Authors: Yi-Min Zhang; Xin-Tong Wu; Jun-Zhe Yi; Jie Xu; Yu-Nan Zhang; Ning Lyu; Ming Zhao
• Keywords: Atezolizumab; FOLFOX; Regimen

Introduction: Previous phase 3 FOHAIC-1 study demonstrated that hepatic arterial infusion chemotherapy (HAIC) of FOLFOX regimen displayed favorable outcomes in advanced hepatocellular carcinoma (HCC) patients, including those with high-risk features (main portal tumor invasion and > 50% liver infiltration). This aimed to compare the treatment efficacy HAIC-FOLFOX versus atezolizumab-bevacizumab HCC patients. Methods: Individual patient data from Chinese aggregate global IMbrave150 were used conduct an anchored matching-adjusted indirect comparison (MAIC). Hazard ratios (HR) restricted mean survival times (RMST) calculated assess differences. Landmark analysis was performed evaluate time-sensitive effects, simulated (STC) conducted as sensitivity analysis. Rates treatment-related adverse events (TRAEs) TRAE-related discontinuations also compared. Results: After matching baseline characteristics, HAIC showed a numerical OS benefit (HR 0.57, 95% CI, 0.30–1.08) similar PFS 0.79, 0.43–1.47) compared overall population. In significantly improved 0.30, 0.12–0.72) 2.89-month longer RMST (95% 0.15–5.64 months). Additionally, superior 0.25, 0.10–0.64) 2.88-month over 0.90–4.86). group revealed associated significant improvements both 0.32, 0.13–0.79) 0.24, 0.09–0.63) during 0–12 months following initiation. Sensitivity using STC yielded consistent results. lower rates grade 3-4 TRAEs discontinuation population group. Conclusion: provided benefits safety profile